Unmet needs in the management of acute myocardial infarction: Role of novel protease-activated receptor-1 antagonist vorapaxar

Vascular Health and Risk Management

Volumn 10, Issue , 2014, Pages 177-188

  Cho, Jung Rae ^a   Rollini, Fabiana ^a   Franchi, Francesco ^a   Ferrante, Elisabetta ^a   Angiolillo, Dominick J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Antiplatelet agent; Platelet aggregation; Protease activated receptor 1; Vorapaxar

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PLACEBO; THIENOPYRIDINE DERIVATIVE; VORAPAXAR;

ACUTE HEART INFARCTION; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CLINICAL PRACTICE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; HEALTH CARE NEED; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING;

ANTIPLATELET AGENT; PLATELET AGGREGATION; PROTEASE-ACTIVATED RECEPTOR 1; VORAPAXAR;

ANIMALS; BLOOD PLATELETS; HEMORRHAGE; HUMANS; LACTONES; MOLECULAR TARGETED THERAPY; MYOCARDIAL INFARCTION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PYRIDINES; RECEPTOR, PAR-1; RECURRENCE; RISK FACTORS; SECONDARY PREVENTION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84898012855     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S36045     Document Type: Review

References (67)

1. Davì G, Patrono C. Platelet activation and atherothrombosis. N Eng J Med. 2007;357(24):2482-2494.
2. Angiolillo DJ, Ueno M, Goto S. Basic principles of platelet biology and clinical implications. Circ J. 2010;74(4):597-607.
3. Ueno M, Kodali M, Tello-Montoliu A, Angiolillo DJ. Role of platelets and antiplatelet therapy in cardiovascular disease. J Atheroscler Thromb. 2011;18(6):431-442.
4. Angiolillo DJ. The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. Drugs. 2012;72(16):2087-2116.
5. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, etal. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007;49(14): 1505-1516.
6. Tantry US, Bonello L, Aradi D, etal. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol. 2013;62(24): 2261-2273.
7. Wiviott SD, Braunwald E, McCabe CH, etal. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001-2015.
8. Wallentin L, Becker RC, Budaj A, etal. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11): 1045-1057.
9. Leon C, Alex M, Klocke A, etal. Platelet ADP receptors contribute to the initiation of intravascular coagulation. Blood. 2004;103(2):594-600.
10. van der Meijden PE, Feijge MA, Giesen PL, Huijberts M, van Raak LP, Heemskerk JW. Platelet P2Y12 receptors enhance signalling towards procoagulant activity and thrombin generation. A study with healthy subjects and patients at thrombotic risk. Thromb Haemost. 2005;93(6):1128-1136.
11. Angiolillo DJ, Capranzano P, Desai B, etal. Impact of P2Y(12) inhibitory effects induced by clopidogrel on platelet procoagulant activity in type 2 diabetes mellitus patients. Thromb Res. 2009;124(3): 318-322.
12. Angiolillo DJ, Capodanno D, Goto S. Platelet thrombin receptor antagonism and atherothrombosis. Eur Heart J. 2010;31(1):17-28.
13. Capodanno D, Bhatt DL, Goto S, etal. Safety and efficacy of protease-activated receptor-1 antagonists in patients with coronary artery disease: a meta-analysis of randomized clinical trials. J Thromb Haemost. 2012;10(10):2006-2015.
14. Tricoci P, Huang Z, Held C, etal. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med. 2012; 366(1):20-23.
15. Morrow DA, Braunwald E, Bonaca MP, etal. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012;366(15):1404-1413.
16. Martorell L, Martínez-González J, Rodríguez C, Gentile M, Calvayrac O, Badimon L. Thrombin and protease-activated receptors (PARs) in atherothrombosis. Thromb Haemost. 2008;99(2):305-315.
17. Ueno M, Ferreiro JL, Angiolillo DJ. Mechanism of action and clinical development of platelet thrombin receptor antagonists. Expert Rev Cardiovasc Ther. 2010;8(8):1191-1200.
18. Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost. 2005;3(8):1800-1814.
19. Kahn ML, Zheng YW, Huang W, etal. A dual thrombin receptor system for platelet activation. Nature. 1998;394(6694):690-694.
20. Vu T-KH, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell. 1991;64(6):1057-1068.
21. Kahn ML, Nakanish-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest. 1999;103(6):879-887.
22. Xu WF, Anderson H, Whitemore TE, etal. Cloning and characterization of human protease-activated receptor 4. Proc Natl Acad Sci U S A. 1998;95(12):6642-6646.
23. Henriksen RA, Hanks VK. PAR-4 agonist AYPGKF stimulates thromboxane production by human platelets. Arterioscler Thromb Vasc Biol. 2002;22(5):861-866.
24. Covic L, Singh C, Smith H, Kuliopulos A. Role of PAR4 thrombin receptor in stabilizing platelet-platelet aggregates as revealed by a patient with Hermansky-Pudlak syndrome. Thromb Haemost. 2002;87(4):722-727.
25. Lova P, Campus F, Lombardi R, etal. Contribution of protease-activated receptors 1 and 4 and glycoprotein Ib-IX-V in the G(i)-independent activation of platelet Rap1B by thrombin. J Biol Chem. 2004;279(24): 25299-25306.
26. Smith CC, Wilson AP, Prichard BN, Betteridge DJ. Stimulus-induced release of endogenous catecholamines from human washed platelets. Clin Sci (Lond). 1986;70(5):495-500.
27. Henn V, Slupsky JR, Grafe M, etal. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998;391(6667):591-594.
28. Stenberg PE, McEver RP, Shuman MA, Jacques YV, Bainton DF. A plateletalpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J Cell Biol. 1985;101(3): 880-886.
29. Offermanns S, Toombs CF, Hu YH, Simon MI. Defective platelet activation in G alpha(q)-deficient mice. Nature. 1997;389(6647):183-186.
30. Kato Y, Kita Y, Hirasawa-Taniyama Y, etal. Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig. Eur J Pharmacol. 2003;473(2-3):163-169.
31. Chackalamannil S, Davies RJ, Asberom T, Doller D, Leone D. A highly efficient total synthesis of (+)-himbacine. J Am Chem Soc. 1996;118(40):9812-9813.
32. Doller D, Chakalamannil S, Czarniecki M, McQuade R, Ruperto V. Design, synthesis, and structure-activity relationship studies of himbacine derived muscarinic receptor antagonists. Bioorg Med Chem Lett. 1999;9(6):901-906.
33. Xia Y, Chackalamannil S, Greenlee WJ, etal. Discovery of a vorapaxar analog with increased aqueous solubility. Bioorg Med Chem Lett. 2010;20(22):6676-6679.
34. Kosoglou T, Reyderman L, Tiessen R, etal. TRAP-induced platelet aggregation following single and multiple rising doses of SCH 530348, a novel thrombin receptor antagonist, in healthy volunteers. Pharmacol Ther. 2009;85(Suppl 1):S21.
35. Kosoglou T, Reyderman L, Tiessen RG, etal. Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects. Eur J Clin Pharmacol. 2012;68(3):249-258.
36. Kosoglou T, Reyderman L, Kasserra C, etal. No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects. Eur J Clin Pharmacol. 2012;68(3):291-300.
37. Becker RC, Moliterno DJ, Jennings LK, etal. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomized, double-blind, placebo-controlled phase II study. Lancet. 2009;373(9667):919-928.
38. Business Wire. Merck says additional information provided to investigators in clinical study of vorapaxar. 2011. Available from: http://www.businesswire.com/news/home/20110119006900/en/Merck-Additional-Information-Investigators-Clinical-Study-Vorapaxar. Accessed January 3, 2014.
39. Leonardi S, Tricoci P, White HD, etal. Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRACER) trial. Eur Heart J. 2013;34(23):1723-1731.
40. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD. Third universal definition of myocardial infarction. J Am Coll Cardiol. 2012;60(16):1581-1598.
41. Whellan DJ, Tricoci P, Chen E, etal. Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial. J Am Coll Cardiol. Epub November 6, 2013.
42. Boyle EM Jr, Lille ST, Allaire E, Clowes AW, Verrier ED. Endothelial cell injury in cardiovascular surgery: atherosclerosis. Ann Thorac Surg. 1997;63(3):885-894.
43. Reilly CF, McFall RC. Platelet-derived growth factor and transforming growth factor beta regulate plasminogen activator inhibitor-1 synthesis in vascular smooth muscle cells. J Biol Chem. 1991;266(15): 9419-9427.
44. Verrier ED, Boyle EM Jr. Endothelial cell injury in cardiovascular surgery. Ann Thorac Surg. 1996;62(3):915-922.
45. Ben-Yehuda O. Vorapaxar in patients undergoing CABG: insights from a subgroup analysis. J Am Coll Cardiol. Epub November 6, 2013.
46. Valgimigli M, Tricoci P, Huang Z, etal. Vorapaxar, a platelet thrombin-receptor antagonist, in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention: results from the TRACER trial. Circulation. 2012;126: A18805.
47. Tricoci P, Huang Z, van de Werf F, etal. Net clinical benefit of vorapaxar in NSTE ACS: role of ischemic and bleeding risk stratification. Circulation. 2012;126:A19049.
48. Tricoci P, Huang Z, van de Werf F, etal. Vorapaxar with and without thienopyridine use in acute coronary syndromes: results from the TRACER trial. Eur Heart J. 2012;33:495-496.
49. Peters RJ, Mehta SR, Fox KA, etal. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation. 2013;108(14):1682-1697.
50. CURRENT-OASIS 7 Investigators, Mehta SR, Bassand JP, etal. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med. 2010;363(10):930-942.
51. Kohli P, Udell JA, Murphy SA, etal. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38). J Am Coll Cardiol. 2014;63(3):225-232.
52. Mahaffey KW, Wojdyla DM, Carroll K, etal. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2011;124(5): 544-554.
53. Mahaffey KW, Huang Z, Wallentin L, etal. Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial). Am J Cardiol. Epub December 25, 2013.
54. Storey RF, Kotha J, Smyth S, etal. Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy. Thromb Haemost. 2014;111(5).
55. Dorsam RT, Tuluc M, Kunapuli SP. Role of protease-activated and ADP receptor subtypes in thrombin generation on human platelets. J Thromb Haemost. 2004;2(5):804-812.
56. Morrow DA, Alberts MJ, Mohr JP, etal. Efficacy and safety of vorapaxar in patients with prior ischemic stroke. Stroke. 2013;44(3):691-698.
57. Scirica BM, Bonaca MP, Braunwald E, etal. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial. Lancet. 2012;380(9850):1317-1324.
58. Scirica BM, Bonaca MP, Morais J, etal. Vorapaxar in patients with diabetes and prior MI: findings from the TRA 2P-TIMI 50 trial. Circulation. 2013;128:A10398.
59. Bonaca MP, Scirica BM, Creager MA, etal. Vorapaxar in patients with peripheral artery disease: results from TRA2°P-TIMI 50. Circulation. 2013;127(14):1522-1529.
60. Bonaca MP, Scirica BM, Braunwald E, etal. Efficacy of vorapaxar is not modified by thienopyridine therapy: results from TRA 2P-TIMI 50 trial. Circulation. 2012;126:A18595.
61. Scirica BM, Bonaca MP, Braunwald E, etal. Vorapaxar for secondary prevention after myocardial infarction according to aspirin dose-insights from the TRA 2P-TIMI 50 trial. Circulation. 2012;126:A14508.
62. Alexander JH, Lopes RD, James S, etal. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365(8):699-708.
63. Oldgren J, Budaj A, Granger CB, etal. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J. 2011;32(22): 2781-2789.
64. Mega JL, Braunwald E, Wiviott SD, etal. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366(1): 9-19.
65. Friedland SN, Eisenberg MJ, Shimony A. Meta-analysis of randomized controlled trials on effect of cilostazol on restenosis rates and outcomes after percutaneous coronary intervention. Am J Cardiol. 2012;109(10): 1397-1404.
66. US Food and Drug Administration. Vorapaxar Advisory Committee briefing document. 2014. Available from: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm381330.pdf. Accessed January 31, 2014.
67. Ferreiro JL, Angiolillo DJ. New directions in antiplatelet therapy. Circ Cardiovasc Interv. 2012;5(3):433-445.